BERLIN (Reuters) -BioNTech said on Monday it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messenger RNA technology (mRNA) in Singapore, in the latest move to expand its production network.
The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023.
BioNTech said its expansion plans were supported by the Singapore Economic Development Board and would increase the global supply of mRNA-based vaccines and establish a production facility in south east Asia to respond rapidly to future pandemics.
“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” said Ugur Sahin, CEO and Co-founder of BioNTech.
Governments around the world are looking to build up local vaccine production to secure access to supplies after manufacturing setbacks have slowed the rollout of COVID-19 doses in some countries.
BioNTech plans to open the Singapore office in 2021 and expects the manufacturing site to be operational by 2023, creating up to 80 jobs in Singapore.
The establishment of a southeast Asia regional hub comes after BioNTech, based in Mainz, Germany, set up a U.S. headquarters in Cambridge, Massachusetts in 2020.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment